Rabab Abdel Moneim | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Rabab Abdel Moneim | Personalized Medicine | Best Researcher Award

Cairo University | Egypt

Prof. Dr. Rabab Abdel Moneim is a distinguished authority in Clinical Oncology at the Kasr El Aini Faculty of Medicine, Cairo University, Cairo, Egypt. With an extensive career dedicated to cancer research, radiotherapy, and clinical practice, she has made a profound impact on oncology education, treatment innovation, and patient care across the Middle East. Her academic foundation was established at the renowned Kasr El Aini Faculty of Medicine, where she completed her M.B.B.Ch. degree with honors, followed by a master’s degree in Medical Oncology and Radiotherapy, earning the highest distinction across all Cairo universities. She later attained her Doctorate in Oncology, cementing her status as a leading scholar and clinician in the field.Prof. Abdel Moneim has accumulated rich professional experience through her long-standing affiliation with the Kasr El Aini Faculty of Medicine, where she has served in multiple academic and clinical capacities, advancing from house officer and resident to assistant lecturer, assistant professor, and eventually full professor. Her clinical expertise is reflected in her consultancy roles at the New Kasr El-Eini Teaching Hospital and the IMC Hospital Radiotherapy Center. Her early professional journey includes collaboration with Prof. Dr. Hamdy Abd El Azim at the Cairo Cure Center, a partnership that shaped her clinical vision and deepened her specialization in oncology and radiotherapy.Her professional experience extends beyond Egypt, having served as a consultant at King Fahd Hospital in Madina, Saudi Arabia, and maintaining an active registration with the Saudi Commission for Health Specialties in Oncology Medicine. Prof. Abdel Moneim’s commitment to global oncology advancement is further demonstrated through her participation in numerous international conferences and workshops, including ESMO, ESTRO, ASCO, and other major oncology congresses. Her contributions to evidence-based cancer therapy, radiotherapy techniques, and the facilitation of clinical trials across the MENA region have significantly influenced modern oncology practices.An active member of multiple professional societies such as ESTRO, ESMO, the Sarcoma Group, and the Neuro-Oncology Group at Cairo University, Prof. Abdel Moneim continues to contribute to academic excellence and clinical innovation. Her expertise in 3D conformal radiation therapy, stereotactic techniques, IMRT, and RapidArc has set a high standard in radiotherapy advancements. As a dedicated educator, she remains involved in postgraduate teaching and training programs, nurturing the next generation of oncologists.

Profile: Google Scholar

Featured Publications

Abdel Moneim, A. A. R., & El Deeb, M. (2017). Gingival pigmentation: Cause, treatment, and histological preview. Future Dental Journal.

Rady, D., Mubarak, R., & Abdel Moneim, R. A. (2018). Healing capacity of bone marrow mesenchymal stem cells versus platelet-rich fibrin in tibial bone defects of albino rats: An in vivo study. F1000Research.

Abdel Moneim, R. A., El Deeb, M., & Adel, F. (2018). Evaluation of the therapeutic potential of Tamarind seeds (aqueous extract) versus antidiabetic drugs on the histological structure of lingual papillae in diabetic rats. Egyptian Dental Journal, 64(3), Oral Medicine, X-Ray, Oral Biology Section.

Hakam, H. M., Abdel Moneim, R. A., & El Deeb, M. F. (2020). Osteoinductive potential and bone healing capacity of nanocrystalline hydroxyapatite (nHA) versus Biodentine of surgically created defects in rabbits’ alveolar process (an experimental study). Egyptian Journal of Histology.

Abdel Moneim, R. A., Mostafa, A., & Abbass, M. M. S. (2020). In treating glucocorticoid-induced osteoporosis in temporomandibular joint of albino rats; which are more effective: Microvesicles or mesenchymal stem cells? Egyptian Journal of Histology.

El Deeb, M., & Abdel Moneim, R. A. (2018). Remineralization potential of lactose-free and plant-based milk on enamel surface of human teeth subjected to energy drinks. Egyptian Dental Journal, 64(4), Oral Medicine, X-Ray, Oral Biology Section.

Ragaei, A., & Abdel Moneim, R. A. A. (2017). Gingival overgrowth: Drug-induced versus hereditary and idiopathic. Cosmetology & Oro Facial Surgery.

Biaoru Li | Personalized Medicine | Oncolog Oncopharm Research Achievement

Published on by Top Pharmaceutical

Dr. Biaoru Li | Personalized Medicine | Oncolog Oncopharm Research Achievement

Medical College of GA | United States

Dr. Biaoru Li is an accomplished leader in the fields of precision medicine, genomics, and personalized immunotherapy, with extensive experience spanning clinical hematology, oncology, and advanced molecular research. His expertise bridges the continuum from bio-specimen preparation to clinical application, integrating cutting-edge biobanking, primary cell sorting, single-cell identification, and functional genomics. Dr. Li’s research delves deeply into the cellular and molecular mechanisms that drive disease, with a particular focus on CD34 cells, erythroid cells, T-cells, and primary tumor cells. His work emphasizes the transformation of primary bio-specimens into powerful genomic insights through advanced technologies such as next-generation sequencing (NGS) and microarray analysis.A pioneer in precision medicine, Dr. Li has made substantial contributions to the development of personalized immunotherapy strategies and the integration of artificial intelligence into biomedical research. His ongoing projects include the design of AI-driven models that enhance diagnostic accuracy and therapeutic prediction for cancer and immune-related disorders. Dr. Li’s innovative research on single-cell RNA sequencing has opened new pathways for individualized treatment, offering a molecular-level understanding of disease heterogeneity.As an academic and clinical researcher, Dr. Li has established collaborations with hospitals and research institutions across the United States and Asia, promoting global scientific exchange and clinical translation. His scholarly impact is reflected in his numerous publications indexed in prestigious scientific databases such as SCI and Scopus, as well as his extensive citation record on Google Scholar and ORCID. Dr. Li’s editorial influence extends across 17 international editorial boards, where he contributes to advancing scientific standards in molecular medicine and clinical genomics.In addition to his academic achievements, Dr. Li has authored influential books, including Personalized Immunotherapy for Tumor Disease and Beyond and Personalized Therapy for PAH and Beyond, both of which underscore his leadership in developing targeted therapeutic frameworks. His membership in renowned professional societies, including the American Society of Hematology and the Royal Society of Medicine, underscores his commitment to advancing medical science and mentoring future researchers.

Profile: Orcid

Featured Publications

Li, S., & Li, B. (2025). Precision medicine related to landscape and architecture of tumor specimen. Japan Journal of Research.

Song, P., & Li, B. (2025). New generation of clinical epigenetics analysis and diagnosis for precision medicine. Diagnostics.

Palani, C. D., Smith, A., Cao, X., Li, B., Pace, B. S., & Starlard‐Davenport, A. (2025). Cholesterol‐conjugated miR‐29b induces fetal haemoglobin expression via γ‐globin promoter demethylation in the Townes mouse model for sickle cell anaemia. British Journal of Haematology.

Yang, Y., Chen, S., Li, W., Duan, J. C., Yuan, Y., Xie, V. S., & Li, B. (2024). STAT3 down-regulation for IL-2 inducing TIL-A clinical clue for spatial quantitative pathway analysis. AIMS Allergy and Immunology.

Li, B. (2024). Surgery and specimen biobanks—Tumor tissues and precision medicine. Journal of Surgery.

Li, B. (2024). Prediction, prevention, prognostic and personalized therapy of ovarian cancer—Biomarkers and precision medicine. Biomedical Journal of Scientific and Technical Research.

Yang, Y., Li, W., Chen, S., Yuan, Y., & Li, B. (2023). Spatial-timely quantitative network analysis for TGF-β pathway of tumor infiltrating lymphocytes. Journal of Cancer Science and Clinical Therapeutics.

Zhu, X., & Li, B. (Eds.). (2023). Epigenetics in cancer: Mechanisms and drug development – Volume II. Frontiers Research Topics.

Li, B. (2023). Personalized immunotherapy of patients: Defining by single-cell RNA-seq with artificial intelligence. Medical Research Archives.

Giorgio Gargari | Personalized Medicine | Best Paper Award

Published on by Top Pharmaceutical

Assist. Prof. Dr. Giorgio Gargari | Personalized Medicine | Best Paper Award

University of Milan | Italy

Assist. Prof. Dr. Giorgio Gargari is an accomplished researcher and academic in the Department of Food, Environmental and Nutritional Sciences at the University of Milan. His academic and research journey reflects a deep commitment to advancing the understanding of the intricate relationships between diet, the gut microbiome, and host physiology. With a strong foundation in biological sciences and food sciences, Dr. Gargari has developed expertise that bridges molecular biology, bioinformatics, and nutritional science, focusing on how dietary interventions influence microbiome composition and functionality. He is a highly skilled bioinformatician and biostatistician, proficient in computational biology, data analysis, and multi-omics integration. His work explores the triangular interaction between diet, microbiome, and host systems, aiming to elucidate how microbial ecosystems mediate the effects of food on health. His scientific approach integrates both experimental and computational methods to identify microbial pathways that contribute to human health and disease prevention. Dr. Gargari’s research has provided valuable insights into gut microbiome modulation through probiotics, polyphenol-rich diets, and microbial metabolites such as short-chain fatty acids. His publications demonstrate his capacity to translate complex biological data into clinically meaningful applications, particularly in the context of inflammatory regulation, gastrointestinal health, and precision nutrition.Dr. Gargari has published extensively in high-impact, peer-reviewed journals, contributing to a body of literature that continues to shape modern nutritional and microbiome research. His work has gained recognition in international conferences and scientific meetings, where he has been an invited speaker on topics such as microbial ecology in winemaking, gut microbiota modulation, and the metabolic effects of dietary components. He has also contributed to projects funded by major research institutions, coordinating studies on the transformation of agro-food waste into valuable biostimulants and microbial ecosystems for sustainable production.As an educator and academic leader, Dr. Gargari plays an active role in multiple degree programs, including Human Nutrition and Dietetics, Food Technology, and Bioinformatics for Comparative Genomics. He has supervised and mentored numerous students and has served on several thesis committees. His contributions to the scientific community have been recognized through various awards and international honors, reflecting his excellence in research, teaching, and innovation.

Profile: Orcid

Featured Publications

Gargari, G., Meroño, T., Peron, G., Del Bo’, C., Marino, M., Cherubini, A., Andres-Lacueva, C., Kroon, P. A., Riso, P., & Guglielmetti, S. (n.d.). Effect of a polyphenol-rich dietary pattern on subjects aged ≥ 60 years with higher levels of inflammatory markers: Insights into microbiome and metabolome. Microbiome Research Reports.

Marzano, M., Thakur, R. S., Bicciato, S., Raneri, M., Guglielmetti, S., Grassi, F., Mangani, D., De Ponte Conti, B., Pesole, G., Gargari, G., et al. (n.d.). Secretory IgA amplification during immune checkpoint blockade enhances the control of tumor growth by enterotropic T cells. Science Advances.

Laterza, L., Cremon, C., Coppola, G., Settanni, C. R., Maresca, R., Strazzeri, M., Durini, E., Petito, V., Scaldaferri, F., Gargari, G., et al. (n.d.). Multistrain probiotics plus vitamin D improve gut barrier function and gut microbiota composition in irritable bowel syndrome without constipation: Results from a double-blind, randomized, placebo-controlled trial. Nutrients.

Duncan, R., Mantegazza, G., Gargari, G., Pierallini, E., Russo, R., & Guglielmetti, S. (n.d.). Heyndrickxia coagulans LMG S-24828 is a safe probiotic strain capable of germinating in the human gut. Probiotics and Antimicrobial Proteins.

Gargari, G., Mantegazza, G., Taverniti, V., Gardana, C., Valenza, A., Rossignoli, F., Barbaro, M. R., Marasco, G., Cremon, C., Barbara, G., et al. (n.d.). Fecal short-chain fatty acids in non-constipated irritable bowel syndrome: A potential clinically relevant stratification factor based on catabotyping analysis. Gut Microbes.

Speciani, M. C., Gargari, G., Penagini, R., Mutignani, M., Ferraroni, M., Natale, A., Katsoulis, M., Cintolo, M., Leone, P., Airoldi, A., et al. (n.d.). Garlic consumption in relation to colorectal cancer risk and to alterations of blood bacterial DNA. European Journal of Nutrition.

Mutignani, M., Penagini, R., Gargari, G., Guglielmetti, S., Cintolo, M., Airoldi, A., Leone, P., Carnevali, P., Ciafardini, C., Petrocelli, G., et al. (n.d.). Blood bacterial DNA load and profiling differ in colorectal cancer patients compared to tumor-free controls. Cancers.

Jl Clua-Espuny | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Assist Prof. Dr. Jl Clua-Espuny | Personalized Medicine | Best Researcher Award

Ebrictus Group at IDIAP Jordi Gol | Spain

Assist. Prof. Dr. JL Clua-Espuny is a distinguished academic and healthcare professional with extensive experience in medicine, primary healthcare, and medical education. He has served in various leadership and academic roles across prestigious institutions, including Universitat Rovira i Virgili, Universidad Miguel Hernández de Elche, and the Institut Català de la Salut. His expertise spans family medicine, health policy, and clinical research, with a strong commitment to improving patient care and medical training. Throughout his career, he has mentored numerous doctoral candidates, contributed to healthcare policy initiatives, and advanced research in cardiovascular diseases, primary care innovation, and public health strategies.

Publication Profile 

Orcid

Education 

Assist. Prof. Dr. JL Clua-Espuny holds multiple advanced degrees, including a Doctorate in Medicine and a Master’s in Primary Care from Universidad Miguel Hernández de Elche. He also completed specialized master’s programs in Health Economics and Healthcare Management from the University of Barcelona and advanced training in Quality Management at Universidad Autonoma de Barcelona and Fundació Avedis Donabedian. Additionally, he earned postgraduate diplomas in Primary Care Management and Quality Evaluation Methodologies and holds dual degrees in Medicine and Philosophy/Psychology from the University of Barcelona. His academic path reflects a dedication to integrating medical, administrative, and research excellence to improve healthcare delivery systems.

Experience 

Assist. Prof. Dr. JL Clua-Espuny career spans healthcare, academia, and research. He served as Director of Primary Care at the Institut Català de la Salut, Vice-President of the Health Council in Tortosa, and Coordinator of Health Plans for the Catalan Health Service. In academia, he has been a professor and tutor at Universitat Rovira i Virgili and Universidad Miguel Hernández de Elche, guiding numerous doctoral and master’s theses. His research affiliations include the Institut Recerca IDIAP Jordi Gol. He has combined clinical practice, academic instruction, healthcare leadership, and policy planning, contributing significantly to primary care innovations and medical education reforms in Spain.

Awards and Honors 

Assist. Prof. Dr. JL Clua-Espuny has received multiple honors for his contributions to medicine, education, and research. He earned the Premio Extraordinario de Doctorado for academic excellence and has been recognized for advancing primary healthcare research and education in Catalonia. His leadership roles in healthcare institutions and medical associations highlight his influence in shaping health policy and service delivery. He has been invited to collaborate in national and regional healthcare planning, reflecting his reputation as an expert in primary care management and cardiovascular health research. His mentorship of numerous doctoral theses further illustrates his commitment to academic excellence and professional development.

Research Focus 

Assist. Prof. Dr. JL Clua-Espuny research centers on primary healthcare, cardiovascular disease prevention, public health interventions, and healthcare quality improvement. He has led and collaborated on projects investigating atrial fibrillation, ischemic stroke, heart failure, and healthcare service optimization. His work often bridges clinical practice with public health policy, emphasizing early detection, risk stratification, and health outcomes in community settings. He has contributed extensively to evaluating the economic impact of chronic diseases, vaccination strategies, and integrated care models. His multidisciplinary approach combines epidemiology, clinical research, and healthcare management to develop innovative strategies for improving patient outcomes and enhancing primary care systems.

Publication Top Notes

Estado de malnutrición como factor pronóstico de eventos cardiovasculares adversos mayores (MACE) en los pacientes con fibrilación auricular

Recent-onset atrial fibrillation: challenges and opportunities

Integrating Lung Ultrasound and the HEFESTOS Score in the Outpatient Heart Failure Management: A Prospective Cohort Study

Prediction of Major Adverse Cardiovascular Events in Atrial Fibrillation: A Comparison Between Machine Learning Techniques and CHA2DS2-VASc Score

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Abordaje extrahospitalario y hospitalario del ictus en fase aguda

Detección precoz de la fibrilación auricular a través de alteraciones en la onda P en el electrocardiograma (ECG) y la disfunción auricular en el ecocardiograma transtorácico (ETT) (póster)

Evidence Gaps and Lessons in the Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)

Evidence Gaps and Lessons in Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)

The Predictive Potential of C-Peptide in Differentiating Type 1 Diabetes From Type 2 Diabetes in an Outpatient Population in Abu Dhabi.

Sex Disparities in the Direct Cost and Management of Stroke: A Population-Based Retrospective Study

Prognostic Significance of Lung Ultrasound for Heart Failure Patient Management in Primary Care: A Systematic Review

Conclusion

Given his extensive research supervision, academic leadership, healthcare experience, and contributions to primary care and public health research, Assist. Prof. Dr. JL Clua-Espuny is highly suitable for the Best Researcher Award. His decades of service, combined with scientific innovation, educational mentorship, and healthcare leadership, position him as a strong candidate. By expanding global research collaborations and enhancing the international dissemination of his work, he could further elevate his impact in the field.

Pedro Moltó-Balado | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Pedro Moltó-Balado | Personalized Medicine | Best Researcher Award

Doctor at Ministry of Health | Spain

Dr. Pedro Moltó-Balado is a dedicated medical professional currently associated with the Ministry of Health, Spain. With a background in family and community medicine, he has combined clinical expertise with research innovation to advance patient care processes and public health initiatives. He has pursued advanced studies in biomedicine, patient care management, and headache specialization while contributing extensively to scientific publications across medical disciplines. His work encompasses cardiovascular health, mental health, primary care innovations, and clinical risk assessment, with a strong commitment to integrating machine learning and advanced diagnostic strategies in healthcare to enhance patient outcomes and medical decision-making.

Publication Profile 

Orcid

Education 

Dr. Pedro Moltó-Balado holds a Graduate in Medicine from Terres de l’Ebre Teaching Unit, Catalonia, Spain. He specialized in Family and Community Medicine through Francisco de Vitoria University and pursued a Ph.D. in Biomedicine from Rovira i Virgili University. Additionally, he completed postgraduate certifications as a University Expert in Headaches and in the Management of Patient Care Processes from Jaime I University and the University of Valencia, respectively. He has undergone specialized health training and participated in continuous academic development across medical law, healthcare management, and clinical research, strengthening his expertise in multidisciplinary healthcare and evidence-based medical practices.

Experience 

Dr. Pedro Moltó-Balado has been actively involved in healthcare practice and academic research through the Ministry of Health and academic institutions in Spain. He has contributed as a corresponding author and researcher in multiple peer-reviewed scientific journals, focusing on primary care innovations, cardiometabolic diseases, and neurological conditions. His professional engagements include clinical research in atrial fibrillation, stroke prevention, metabolic disorders, and rare medical conditions, along with implementing patient-centered healthcare strategies. He has also participated in academic teaching, supervising research projects, and contributing to medical education programs while collaborating with healthcare organizations to translate clinical research into practical healthcare solutions.

Awards and Honors 

Dr. Pedro Moltó-Balado has been recognized for his research contributions and academic excellence in family and community medicine, cardiometabolic health, and primary care innovation. His work on early diagnosis in cardiovascular medicine, clinical risk prevention, and rare disease case studies has been acknowledged through conference presentations, academic collaborations, and peer-reviewed scientific publications. He has contributed to international research forums and interdisciplinary projects that integrate clinical practice with technological innovation, including machine learning applications in healthcare. His commitment to advancing evidence-based medical practices has earned him recognition in medical research communities focused on improving public health outcomes.

Research Focus 

Dr. Pedro Moltó-Balado’s research focuses on cardiovascular risk prediction, primary care optimization, and integrating technology into clinical diagnostics. His studies explore early detection of atrial fibrillation, stroke prevention strategies, metabolic disorders, and neurological complications in primary healthcare settings. He has worked on machine learning models for predicting major adverse cardiovascular events, case studies on rare conditions such as pheochromocytoma and rhinocerebral mucormycosis, and management approaches for psychiatric medication complications. His multidisciplinary approach bridges clinical medicine, data analytics, and patient care strategies, aiming to develop innovative diagnostic tools and risk assessment methods that improve healthcare decision-making and patient safety outcomes.

Publication Top Notes

Estado de malnutrición como factor pronóstico de eventos cardiovasculares adversos mayores (MACE) en los pacientes con fibrilación auricular

Prediction of Major Adverse Cardiovascular Events in Atrial Fibrillation: A Comparison Between Machine Learning Techniques and CHA2DS2-VASc Score

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Algo más que una coxalgia: necrosis avascular de cabeza femoral

Aripiprazole: Beware of pathological gambling addiction,Aripiprazol: cuidado con la adicción patológica al juego

Mucormicosis tras una picadura de araña

The Future of Healthcare: Biomedical Technology and Integrated Artificial Intelligence

Oleoma glúteo: consecuencias del tratamiento intramuscular

Machine Learning Approaches to Predict Major Adverse Cardiovascular Events in Atrial Fibrillation

Conclusion

Dr. Pedro Moltó-Balado’s academic achievements, innovative research in cardiometabolic and primary care medicine, and integration of technology into clinical diagnostics make him a highly suitable candidate for the Best Researcher Award. His dedication to improving patient outcomes through evidence-based research and his contributions to medical literature align well with the award’s objectives. With continued emphasis on global collaborations and translational research, his work has the potential to make significant advancements in public health and medical science.

Maria Garrido | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Dr. Maria Garrido | Personalized Medicine | Women Researcher Award

Doctor at Hospital Universidtario 12 de octubre-Universidad Complutense de Madrid | Spain

Dr. Maria Garrido is a physician-scientist specializing in pathology and translational oncology with a focus on melanoma and cutaneous lymphomas. She earned her medical degree from the University of Granada and her PhD in Health Sciences and Biomedicine from Universidad Complutense de Madrid. With extensive international experience at the University of California San Francisco and Memorial Sloan Kettering, her research has contributed to landmark discoveries in oncogenes, fusion kinases, and tumor biomarkers. She currently works in dermatopathology and oncology research, collaborating with leading groups in Europe and internationally to advance personalized cancer diagnostics and therapeutic strategies.

Publication Profile 

Orcid

Education 

Dr. Maria Garrido obtained her medical degree in Medicine and Surgery from the University of Granada. She pursued her residency in Anatomical Pathology at Hospital Universitario 12 de Octubre, Madrid, and later completed a PhD in Health Sciences and Biomedicine at Universidad Complutense de Madrid. Complementing her medical and scientific training, she earned a Master’s in Clinical Management, Medical, and Healthcare Leadership from Universidad Tecnológica. Her academic formation integrates rigorous clinical foundations with molecular oncology research, allowing her to bridge patient care and translational science. She has continued to enhance her expertise through national and international academic fellowships.

Experience 

Dr. Maria Garrido has served as a resident and clinical specialist in pathology at major Spanish hospitals, including Hospital 12 de Octubre, Hospital General de Móstoles, and Clinic Hospital of Barcelona. Internationally, she was a fellowship researcher at UCSF and Memorial Sloan Kettering, contributing to melanoma genetics and translational oncology. She has collaborated on groundbreaking discoveries, including oncogenes in uveal melanoma and fusion kinases in Spitz tumors. Currently, she is part of the dermatopathology and oncology research group at Hospital Universitario 12 de Octubre, Madrid, where she advances studies on melanoma, lymphomas, molecular biomarkers, and diagnostic innovations in cutaneous oncology.

Awards and Honors 

Dr. Maria Garrido has received notable recognition for her research contributions. She was awarded a mobility fellowship by the Spanish Ministry of Science and Innovation for professional development in computational pathology at Queen’s University, Belfast. Her discoveries, including the GNA11 oncogene and fusion kinases in melanocytic tumors, have been published in high-impact journals such as the New England Journal of Medicine, Nature Communications, and Nature Genetics. Her contributions to the field of melanoma genetics have been cited worldwide, shaping the understanding of tumor biology. She continues to be honored through invitations to collaborate on international research initiatives and networks.

Research Focus 

Dr. Maria Garrido research focuses on the molecular pathology of melanoma and cutaneous lymphomas. She has made significant contributions to identifying oncogenes such as GNA11 and GNAQ, which account for most uveal melanomas, and discovering kinase fusion proteins in Spitz tumors. Her work also includes genetic studies on desmoplastic melanoma highlighting NFKBIE mutations. More recently, she has contributed to refining the classification of cutaneous lymphomas and identifying new biomarkers to guide diagnosis, prognosis, and therapeutic response. Her approach integrates pathology, molecular biology, and translational medicine to improve personalized treatment strategies and enhance patient outcomes in oncology and dermatopathology.

Publication Top Notes

Advanced Periocular Basal Cell Carcinoma with Orbital Invasion: Update on Management and Treatment Advances

Acute sarcoidosis as a harbinger for pancreatic adenocarcinoma

TERT promoter mutation in sebaceous neoplasms

Orbital Solitary Fibrous Tumor: Four Case Reports—Clinical and Histopathological Features

Conjunctival Tarsal Actinic Keratosis Treated with Interferon Alfa-2b: A Rare Case Report and Literature Review

SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma

E Marimuthu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. E. Marimuthu | Drug Discovery and Development | Best Researcher Award

Professor at Arunachal University of Studies | Ayya Nadar Janaki Ammal College | Madurai Kamaraj University | India

Dr. E. Marimuthu is a dedicated researcher and academician specializing in plant biotechnology, microbiology, and molecular biology. With over 15 years of experience in research and education, he has made significant contributions through patents, microbial sequencing, and ethnobotanical surveys. His work focuses on endangered species conservation, natural IAA production, and nanomedicine applications for cancer. Dr. Marimuthu currently serves as a Professor at Arunachal University of Studies. His multidisciplinary efforts bridge traditional knowledge with modern scientific innovations, making him a standout figure in applied life sciences and pharmaceutical biotechnology.

Publication Profile 

Scopus 

Education

Dr. Marimuthu earned his Ph.D. from Madurai Kamaraj University in 2017, focusing on the in vitro conservation of endangered tree species in the Southern Western Ghats . He completed his M.Phil. and M.Sc. from Ayya Nadar Janaki Ammal College, conducting ethnomedicinal surveys and plant growth hormone studies. His academic foundation began with a B.Sc. in Botany. Each academic milestone has been rooted in biodiversity conservation and plant-microbe interactions, establishing a strong base for his later patents and microbial gene discoveries .

Experience

Dr. Marimuthu has held various academic and research roles: Professor and Associate Professor at Arunachal University of Studies (2023–present), Assistant Professor at Sri Vidya Mandir and Vivekanandha Colleges, and Associate Scientist at Aakash Green Research Pvt. Ltd. Earlier, he served as a JRF at TBGRI, Kerala  and Technical Assistant at Kalasalingam University. His experience spans plant tissue culture, cell line work, and microbial molecular studies. With deep involvement in both lab and field research, he has nurtured innovations from concept to patent, while also mentoring students and contributing to curriculum development.

Awards 

Dr. E. Marimuthu is a prolific innovator with 8 Indian patents and 2 Canadian patents, showcasing breakthroughs in nanomedicine, cancer immunotherapy, and plant-based biotechnology . His bacterial gene sequences are submitted to NCBI, emphasizing novel microbial discoveries from unique ecological niches. Recognized nationally and internationally for his translational research, he has pioneered techniques that merge traditional plant knowledge with high-end scientific platforms. Though specific named awards are not listed, his patent record and academic promotions signify a distinguished and respected trajectory in bioscience innovation and interdisciplinary research.

Research Focus 

Dr. Marimuthu’s research emphasizes plant tissue culture, natural growth hormone production, ethnomedicinal conservation, and nanotechnology-enhanced drug delivery . He explores molecular markers for documenting genetic diversity and has successfully isolated bacterial strains producing Indole-3-acetic acid (IAA) to promote plant growth . He integrates ethnobotanical knowledge with biotechnological advancements to develop eco-friendly, scalable solutions for agriculture and medicine. His cutting-edge work in cancer-targeting mesenchymal stem cell therapy, as well as nano-immunotherapy, reflects a visionary outlook on the future of personalized medicine and sustainable pharmacology.

Publication Top Notes

Title: Chemical profiling and in silico molecular docking studies of phytochemicals from Hydnocarpus macrocarpa Warb: A GC–MS, FTIR, and physico-chemical analysis
Journal: Journal of Molecular Structure
Year: 2025

Conclusion

Dr. E. Marimuthu is an outstanding candidate for the Best Researcher Award, showcasing a rare combination of field knowledge, lab precision, patent-oriented innovation, and a commitment to both fundamental and applied science. His work contributes significantly to biotechnology, pharmacology, environmental microbiology, and regenerative agriculture.

Tao Lv | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Tao Lv | Personalized Medicine | Best Researcher Award

Prof. Tao Lv at Qilu Hospital of Shandong University Dezhou Hospital, China.

Dr. Tao Lv is a dedicated and forward-thinking medical researcher specializing in plastic and reconstructive surgery, regenerative medicine, and dermatological science. With a profound interest in wound healing, scar formation, and stem cell therapies, Dr. Lv has actively contributed to advancing medical knowledge through impactful clinical studies and translational research. His multidisciplinary collaborations have yielded significant breakthroughs in scar prevention and fat grafting techniques, offering new hope to patients undergoing reconstructive procedures. He has co-authored peer-reviewed publications in top-tier journals such as Annals of Plastic Surgery, Aesthetic Plastic Surgery, Stem Cells Translational Medicine, and Frontiers in Cell and Developmental Biology. Driven by scientific rigor and patient-focused innovation, Dr. Lv continues to explore bioactive molecules and cellular therapies to improve outcomes in tissue engineering and plastic surgery. His work is not only appreciated in academia but also among practicing clinicians for its direct application in enhancing post-operative care and long-term patient satisfaction.

Publication Profile 

Scopus

Education

Dr. Tao Lv holds a Ph.D. in a medical or biomedical science discipline (exact major not specified), providing him with an advanced understanding of molecular biology, tissue regeneration, and clinical methodologies. He likely earned his bachelor’s and master’s degrees in related fields such as biology, medicine, or biomedical engineering. During his academic journey, he developed strong expertise in cellular mechanisms, biochemistry, and clinical trial design, which laid the foundation for his success in regenerative and reconstructive medicine. Dr. Lv’s academic training emphasized interdisciplinary research, laboratory techniques, and translational approaches to tackle real-world clinical challenges. As reflected in his publications, he worked closely with both research and clinical departments, blending scientific exploration with practical outcomes in surgery and therapeutics. His academic milestones have been integral to his capacity to lead and collaborate in cutting-edge studies. Dr. Lv’s educational background not only sharpened his technical competencies but also fostered a deep appreciation for patient-centric research.

Experience

Dr. Tao Lv has amassed considerable experience in biomedical and clinical research, focusing particularly on scar modulation, fat grafting, and mesenchymal stem cell behavior. His professional journey includes roles in both academic institutions and clinical research settings, where he collaborated with surgeons, dermatologists, and biomedical scientists. One of his standout contributions was exploring the dose-dependent effects of Botulinum Toxin Type A in scar prevention across different body regions—an innovative, randomized controlled trial published in 2025. He has also been part of a research team examining differences in human skin and hypertrophic scar tissue based on age, location, and maturity, further emphasizing his commitment to personalized and patient-specific medical solutions. In 2019, his work on using Fructose 1,6-Bisphosphate as a protective agent in experimental fat grafting marked a breakthrough in stem cell translational therapy. He has also investigated how CXCL2 affects mesenchymal stem cell function in high-fat diet-fed rats, bridging metabolic health with regenerative biology. Through his roles, Dr. Lv has gained expertise in clinical study design, patient care, molecular diagnostics, and regenerative interventions. His integrative approach helps bridge the gap between bench and bedside.

Awards 

While specific awards and honors are not mentioned in the provided content, Dr. Tao Lv’s prolific publication history in high-impact, peer-reviewed journals suggests he is a highly respected figure in the fields of regenerative medicine and plastic surgery research. His studies have likely earned recognition in national and international medical symposia and research forums. The consistent quality and relevance of his work—including randomized controlled trials and translational stem cell therapies—imply nominations or receipt of research grants, young investigator awards, or conference best-paper recognitions. Publications in prestigious journals like Stem Cells Translational Medicine, Aesthetic Plastic Surgery, and Annals of Plastic Surgery reflect his status as a thought leader. Given his multi-institutional collaborations and interdisciplinary approach, Dr. Lv is likely affiliated with academic or hospital research institutions that value innovation and clinical impact. His honors may include acknowledgments for advancing scar treatment, improving cosmetic outcomes post-surgery, and exploring metabolic impacts on cell biology. Future accolades may further solidify his legacy as a pioneer in integrating stem cell therapy and scar modulation into clinical practice.

Research Focus 

Dr. Tao Lv’s research is deeply rooted in regenerative medicine, scar prevention, and the application of biologics in aesthetic and reconstructive procedures. He focuses on understanding tissue response in hypertrophic scarring and identifying therapeutic interventions using agents like Botulinum Toxin Type A. One of his major research interests includes fat grafting, where he explored the protective effects of Fructose 1,6-Bisphosphate to enhance graft viability. Another vital area of his work investigates how CXCL2 impairs mesenchymal stem cell function, particularly under high-fat dietary conditions, merging insights from metabolic disease and cell biology. Dr. Lv is also dedicated to comparative tissue analysis—such as assessing skin versus scar tissue across age groups and anatomical sites—to inform personalized treatment strategies. His translational approach combines bench-side discoveries with patient-centered outcomes. By using clinical trial methodologies and molecular tools, he addresses both acute and chronic issues in surgical healing and tissue regeneration. Overall, his research aims to enhance healing, reduce fibrosis, and improve long-term cosmetic and functional outcomes, making a significant impact on the fields of plastic surgery and tissue engineering.

Publication Top Notes

  • Dose-Dependent Effects of Botulinum Toxin Type A on Prevention of Postoperative Scars in Various Regions in the Body: A Prospective, Double-Blind Randomized Controlled Trial

Jonathan Ejie | Personalized Medicine | Best Research Article Award

Published on by Top Pharmaceutical

Jonathan Ejie | Personalized Medicine | Best Research Article Award

Mr. Jonathan Ejie, UCSF, United States

Mr. Jonathan Ejie is an aspiring physician-scientist currently pursuing his M.D. at UCSF 🩺 (Class of 2026), following a B.S. in Electrical Engineering & Computer Science from UC Berkeley 💻. His research spans oncology, radiology, and AI in healthcare, with published work in Cancers (2025) and upcoming studies in Nature Communications 📊. Jonathan integrates data science 🧠 with clinical insights, contributing to health equity, quality improvement, and surgical education. A mentor, tutor, and award-winning leader 🏅, he co-founded the UCSF Futbol Club and serves underserved communities through advocacy and outreach.

Publication Profile 

Orcid

Education

Mr. Jonathan Ejie is an exceptional scholar whose educational journey bridges medicine and technology. He is currently pursuing his Doctor of Medicine (M.D.) degree at the prestigious University of California, San Francisco (UCSF) 🏥, with an expected graduation in 2026. Prior to this, he earned a Bachelor of Science in Electrical Engineering and Computer Science (EECS) 💻 from the University of California, Berkeley, graduating in 2022. His strong foundation in both engineering and clinical science equips him with a unique interdisciplinary perspective 🤖🩺, positioning him at the forefront of innovation in digital health and precision medicine.

Experience

Mr. Jonathan Ejie brings a blend of academic support and compassionate service to his professional journey. As an MCAT Physics Tutor at UCSF (2023), he guided 15+ students through complex physics concepts 📘⚛️. Earlier, at Contra Costa College (2019–2021), he tutored mathematics from Algebra to Calculus ➕📐. His volunteer work includes providing first aid at athletic events 🏃‍♂️🩹, teaching surgical skills to high school students at UCSF 🧵🧑‍⚕️, and serving as a Health Advocate at West County Health Center 💬🩺, helping underserved patients access vital community resources. His dedication reflects a strong commitment to both education and public health.

Awards

Mr. Jonathan Ejie has been recognized for his academic excellence and impactful contributions to medicine and research. In 2024, he was honored with the prestigious Sinkler Miller Medical Association Scholarship 🎖️, sponsored by Gilead, celebrating his commitment to health equity and academic distinction. He also received the UCSF School of Medicine Summer Explore Fellowship Grant 🌟, supporting his innovative pursuits in medical research. In May 2023, Jonathan earned the Inquiry Conference Travel and Dissemination Award ✈️📊, which enabled him to share his scholarly findings on a larger stage. These accolades reflect his rising potential and leadership in healthcare.

Research Focus 

Mr. Jonathan Ejie’s research focus lies at the intersection of oncology, health disparities, and medical data science. His standout work on the “Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer” 📉🩺 highlights critical inequities in healthcare delivery across race, geography, and insurance status. Combining his background in medicine 🧑‍⚕️ and computer science 💻, Jonathan leverages data analysis and machine learning 🤖📊 to drive systemic improvements in cancer care. His work reflects a commitment to equity, evidence-based medicine, and the pursuit of personalized, accessible treatment strategies for vulnerable cancer populations.

Publication Top Notes

  • Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer

Mario Romeo | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Mario Romeo | Precision Medicine | Best Researcher Award

Dr. Mario Romeo, Dipartimento di Medicina di Precisione, Università degli Studi della Campania, LuigiVanvitelli, Italy

Dr. Mario Romeo is an accomplished medical doctor and researcher specializing in Digestive System Diseases. Graduating with top honors in Medicine and Surgery from the University of Campania “Luigi Vanvitelli” 🎓, he also earned a specialization in Gastroenterology and is pursuing a Ph.D. in Clinical and Experimental Medical Sciences. His research spans gut microbiota 🧫, liver disease 🏥, and metabolic dysfunction. A recipient of over 20 international awards 🏆, Dr. Romeo is widely recognized for his groundbreaking work in hepatology and gastroenterology. He actively contributes to scientific societies and fosters innovation in digestive health care.

Publication Profile 

Orcid

Education

Dr. Mario Romeo 🎓 began his academic journey with honors, earning his Diploma di Maturità Classica from Liceo Classico Gneo Nevio in June 2014 with a perfect score of 100/100 con lode 📜. He continued his excellence at the University of Campania “Luigi Vanvitelli,” completing his Laurea in Medicina e Chirurgia in July 2020 with 110/110 con lode 🩺, presenting a thesis on sarcopenia in compensated liver cirrhosis. He further specialized in Digestive System Diseases, earning his diploma in January 2025 with 50/50 con lode 🌟. His thesis explored RPR as a non-invasive tool in liver disease prediction.

Awards

Dr. Mario Romeo 🏅 has received numerous prestigious scholarships and awards in recognition of his excellence in hepatology and gastroenterology. Highlights include competitive fellowships like the AISF MasterClass 2022 🎓 and UEG Clinical Visiting Fellowship 2025 🌍. He has earned multiple travel grants ✈️ and best presentation prizes 🏆 at top events such as UEG Week, FISMAD, EASL, and ESCI for groundbreaking research on liver diseases, MAFLD, gut microbiota, and non-invasive biomarkers. His multidisciplinary “CoCoNut” protocol 🍏 also gained international acclaim. These accolades affirm his dynamic role in advancing liver research and patient care through innovation and collaboration.

Research Focus 

Dr. Mario Romeo’s research focus lies predominantly in Hepatology and Gastroenterology, with a strong emphasis on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), liver cirrhosis, and gut-liver axis dynamics 🧬🍽️. His work explores non-invasive biomarkers, body composition, oxidative stress, and gut microbiota 🧫, highlighting their roles in disease progression and clinical outcomes. He also investigates multidisciplinary management strategies combining nutritional, psychological, and pharmacological interventions 🥗🧠💊. Dr. Romeo contributes significantly to understanding liver-related complications like sarcopenia, dysgeusia, and hepatocellular carcinoma 🎯. His innovative, patient-centered research enhances predictive diagnostics and therapeutic approaches in chronic liver diseases.

Publication Top Notes

  • Spleen Area Affects the Performance of the Platelet Count–Based Non-invasive Tools in Predicting First Hepatic Decompensation in Metabolic Dysfunction–Associated Steatotic Liver Disease Cirrhosis
  • Nutritional and Psychological Support as a Multidisciplinary Coordinated Approach in the Management of Chronic Liver Disease: A Scoping Review
  • Letter: Different Risk of Acute Variceal Bleeding According to the Liver Disease Aetiology in Decompensated Cirrhosis Patients Receiving Carvedilol‐Based Primary Prophylaxis—May Insulin Resistance Unloose This Gordian Knot?
  • Exploring the Classic and Novel Pathogenetic Insights of Plastic Exposure in the Genesis and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • The Role of the Gut–Biliary–Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications
  • Primary biliary cholangitis, Celiac Disease, and MASLD: the triumvirate of steatosis. How should we manage this triple overlap?
  • Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?
  • FLAME: Training and Validating a Newly Conceived Model Incorporating Alpha-Glutathione-S-Transferase Serum Levels for Predicting Advanced Hepatic Fibrosis and Acute Cardiovascular Events in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • Dysgeusia in MASLD-related advanced chronic liver disease (ACLD): a silent driver towards the “Bermuda” triangle of malnutrition-sarcopenia-frailty severely affecting prognosis
  • Vanek’s Tumour as a Rare Cause of Dyspeptic Syndrome in a Patient with Primary Biliary Cholangitis: A Case Report
  • Systemic Oxidative Stress Correlates with Sarcopenia and Pruritus Severity in Primary Biliary Cholangitis (PBC): Two Independent Relationships Simultaneously Impacting the Quality of Life—Is the Low Absorption of Cholestasis-Promoted Vitamin D a Puzzle Piece?
  • Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study